Version 1
: Received: 27 September 2019 / Approved: 29 September 2019 / Online: 29 September 2019 (06:29:54 CEST)
How to cite:
Roomruangwong, C.; Sirivichayakul, S.; Carvalho, A.F.; Maes, M. The Uterine-Chemokine-Brain Axis: Menstrual Cycle-Associated Symptoms (MCAS) are in Part Mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Preprints2019, 2019090329. https://doi.org/10.20944/preprints201909.0329.v1
Roomruangwong, C.; Sirivichayakul, S.; Carvalho, A.F.; Maes, M. The Uterine-Chemokine-Brain Axis: Menstrual Cycle-Associated Symptoms (MCAS) are in Part Mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Preprints 2019, 2019090329. https://doi.org/10.20944/preprints201909.0329.v1
Roomruangwong, C.; Sirivichayakul, S.; Carvalho, A.F.; Maes, M. The Uterine-Chemokine-Brain Axis: Menstrual Cycle-Associated Symptoms (MCAS) are in Part Mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Preprints2019, 2019090329. https://doi.org/10.20944/preprints201909.0329.v1
APA Style
Roomruangwong, C., Sirivichayakul, S., Carvalho, A.F., & Maes, M. (2019). The Uterine-Chemokine-Brain Axis: Menstrual Cycle-Associated Symptoms (MCAS) are in Part Mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Preprints. https://doi.org/10.20944/preprints201909.0329.v1
Chicago/Turabian Style
Roomruangwong, C., Andre F. Carvalho and Michael Maes. 2019 "The Uterine-Chemokine-Brain Axis: Menstrual Cycle-Associated Symptoms (MCAS) are in Part Mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10" Preprints. https://doi.org/10.20944/preprints201909.0329.v1
Abstract
Objective: To examine associations between chemokines and menstrual cycle associated symptoms (MCAS). Methods: Forty-one women completed the Daily Record of Severity of Problems (DRSP) rating scale during 28 consecutive days of the menstrual cycle. MCAS is diagnosed when the total daily DRSP score during the menstrual cycle is > 0.666 percentile. We assayed plasma CCL2, CCL5, CCL11, CXCL8, CXCL10, EGF, IGF-1, and PAI-1 at days 7, 14, 21 and 28 of the menstrual cycle. Results: CCL2, CCL5, CCL11 and EGF are significantly higher in women with MCAS than in those without. Increased CCL2, CXCL10, CXCL8, CCL11 and CCL5 levels are significantly associated with DRSP scores while CCL2 is the most significant predictor explaining 39.6% of the variance. The sum of the neurotoxic chemokines CCL2, CCL11 and CCL5 is significantly associated with the DRSP score and depression, physiosomatic, breast-craving and anxiety symptoms. The impact of chemokines on MCAS symptoms may differ between consecutive weeks of the menstrual cycle with CCL2 being the most important predictor of increased DRSP levels during the first two weeks, and CXCL10 or a combination of CCL2, CCL11 and CCL5 being the best predictors during week 3 and 4, respectively. Discussion: The novel case definition “MCAS” is externally validated by increased levels of uterus-associated chemokines and EGF. Those chemokines are involved in MCAS and are regulated by sex hormones and modulate endometrium functions and brain neuro-immune responses, which may underpin MCAS symptoms. As such, uterine-related chemokines may link the uterus with brain functions via a putative uterine-chemokine-brain axis.
Medicine and Pharmacology, Psychiatry and Mental Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
